Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Zakostelska, Zuzana ^a   Kverka, Miloslav ^a   Klimesova, Klara ^a   Rossmann, Pavel ^a   Mrazek, Jakub ^b   Kopecny, Jan ^b   Hornova, Michaela ^a   Srutkova, Dagmar ^a   Hudcovic, Tomas ^a   Ridl, Jakub ^c   Tlaskalova Hogenova, Helena ^a  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^b INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS   (Czech Republic)

^c INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN SULFATE; DN 114 001; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; GAMMA INTERFERON; INTERLEUKIN 10; PROBIOTIC AGENT; PROTEIN ZO1; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MEMBRANE PROTEIN; PHOSPHOPROTEIN; ZONULA OCCLUDENS-1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOWN REGULATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOFLUORESCENCE TEST; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INTESTINE FUNCTION; INTESTINE MUCOSA PERMEABILITY; LACTOBACILLUS CASEI; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PEYER PATCH; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PYROSEQUENCING; SIGNAL TRANSDUCTION; ACUTE DISEASE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CYTOLOGY; DIGESTIVE SYSTEM; DRUG EFFECT; HUMAN; IMMUNITY; IMMUNOLOGY; INTESTINE MUCOSA; LYMPHOCYTE COUNT; MACROPHAGE ACTIVATION; METABOLISM; METAGENOME; MICROBIOLOGY; MOUSE MUTANT; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; PERMEABILITY; REGULATORY T LYMPHOCYTE;

BACTERIA (MICROORGANISMS); LACTOBACILLUS CASEI; MURINAE; MUS;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANIMALS; COLITIS; DIGESTIVE SYSTEM; DOWN-REGULATION; FEMALE; HUMANS; IMMUNITY; INTESTINAL MUCOSA; LACTOBACILLUS CASEI; LIPOPOLYSACCHARIDES; LYMPHOCYTE COUNT; MACROPHAGE ACTIVATION; MEMBRANE PROTEINS; METAGENOME; MICE; MICE, INBRED BALB C; MICE, SCID; NF-KAPPA B; PERMEABILITY; PHOSPHOPROTEINS; PROBIOTICS; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 81555205689     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027961     Document Type: Article

References (56)

1. Sartor RB, (2006) Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 3: 390-407.
2. Packey CD, Sartor RB, (2009) Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases. Curr Opin Infect Dis 22: 292-301.
3. Sheil B, Shanahan F, O'Mahony L, (2007) Probiotic effects on inflammatory bowel disease. J Nutr 137: 819S-824S.
4. FAO/WHO (2001) Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria Cordoba (Argentina) Food and Agriculture Organization of the United Nations and World Health Organization.
5. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, et al. (2005) VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 100: 1539-1546.
6. Lebeer S, Vanderleyden J, De Keersmaecker SC, (2010) Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev Microbiol 8: 171-184.
7. Servin AL, (2004) Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev 28: 405-440.
8. Gupta P, Andrew H, Kirschner BS, Guandalini S, (2000) Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 31: 453-457.
9. Reiff C, Delday M, Rucklidge G, Reid M, Duncan G, et al. (2009) Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 15: 1721-1736.
10. Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, et al. (2008) Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371: 651-659.
11. Kverka M, Zakostelska Z, Klimesova K, Sokol D, Hudcovic T, et al. (2011) Oral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition. Clin Exp Immunol 163: 250-259.
12. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, et al. (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694-702.
13. Poritz LS, Garver KI, Green C, Fitzpatrick L, Ruggiero F, et al. (2007) Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. J Surg Res 140: 12-19.
14. Yan Y, Kolachala V, Dalmasso G, Nguyen H, Laroui H, et al. (2009) Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis. PLoS One 4: e6073.
15. Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, et al. (1994) Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107: 1643-1652.
16. Dieleman LA, Palmen MJ, Akol H, Bloemena E, Pena AS, et al. (1998) Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 114: 385-391.
17. Kleerebezem M, Vaughan EE, (2009) Probiotic and gut lactobacilli and bifidobacteria: molecular approaches to study diversity and activity. Annu Rev Microbiol 63: 269-290.
18. Hanniffy S, Wiedermann U, Repa A, Mercenier A, Daniel C, et al. (2004) Potential and opportunities for use of recombinant lactic acid bacteria in human health. Adv Appl Microbiol 56: 1-64.
19. Merenstein D, Murphy M, Fokar A, Hernandez RK, Park H, et al. (2010) Use of a fermented dairy probiotic drink containing Lactobacillus casei (DN-114 001) to decrease the rate of illness in kids: the DRINK study. A patient-oriented, double-blind, cluster-randomized, placebo-controlled, clinical trial. Eur J Clin Nutr 64: 669-677.
20. Ingrassia I, Leplingard A, Darfeuille-Michaud A, (2005) Lactobacillus casei DN-114 001 inhibits the ability of adherent-invasive Escherichia coli isolated from Crohn's disease patients to adhere to and to invade intestinal epithelial cells. Appl Environ Microbiol 71: 2880-2887.
21. Kokesova A, Frolova L, Kverka M, Sokol D, Rossmann P, et al. (2006) Oral administration of probiotic bacteria (E. coli Nissle, E. coli O83, Lactobacillus casei) influences the severity of dextran sodium sulfate-induced colitis in BALB/c mice. Folia Microbiol (Praha) 51: 478-484.
22. Wang Q, Fang CH, Hasselgren PO, (2001) Intestinal permeability is reduced and IL-10 levels are increased in septic IL-6 knockout mice. Am J Physiol Regul Integr Comp Physiol 281: R1013-1023.
23. Zanvit P, Tichopad A, Havlickova M, Novotna O, Jirkovska M, et al. (2010) Adjuvant effect of Bacillus firmus on the expression of cytokines and toll-like receptors in mouse nasopharynx-associated lymphoid tissue (NALT) after intranasal immunization with inactivated influenza virus type A. Immunol Lett 134: 26-34.
24. Gontcharova V, Youn E, Wolcott RD, Hollister EB, Gentry TJ, et al. (2010) Black Box Chimera Check (B2C2): a Windows-Based Software for Batch Depletion of Chimeras from Bacterial 16S rRNA Gene Datasets. Open Microbiol J 4: 47-52.
25. Wang Q, Garrity GM, Tiedje JM, Cole JR, (2007) Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 73: 5261-5267.
26. Munkholm P, Langholz E, Hollander D, Thornberg K, Orholm M, et al. (1994) Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives. Gut 35: 68-72.
27. Kitajima S, Takuma S, Morimoto M, (1999) Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. Exp Anim 48: 137-143.
28. Ewaschuk JB, Diaz H, Meddings L, Diederichs B, Dmytrash A, et al. (2008) Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. Am J Physiol Gastrointest Liver Physiol 295: G1025-1034.
29. Ukena SN, Singh A, Dringenberg U, Engelhardt R, Seidler U, et al. (2007) Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One 2: e1308.
30. Fava F, Danese S, (2011) Intestinal microbiota in inflammatory bowel disease: friend of foe? World J Gastroenterol 17: 557-566.
31. Donohoe DR, Garge N, Zhang X, Sun W, O'Connell TM, et al. (2011) The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab 13: 517-526.
32. Hudcovic T, Stepankova R, Cebra J, Tlaskalova-Hogenova H, (2001) The role of microflora in the development of intestinal inflammation: acute and chronic colitis induced by dextran sulfate in germ-free and conventionally reared immunocompetent and immunodeficient mice. Folia Microbiol (Praha) 46: 565-572.
33. Mileti E, Matteoli G, Iliev ID, Rescigno M, (2009) Comparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex culture systems: prediction for in vivo efficacy. PLoS One 4: e7056.
34. Lee JM, Hwang KT, Jun WJ, Park CS, Lee MY, (2008) Antiinflammatory effect of lactic acid bacteria: inhibition of cyclooxygenase-2 by suppressing nuclear factor-kappaB in Raw264.7 macrophage cells. J Microbiol Biotechnol 18: 1683-1688.
35. Matsumoto S, Hara T, Hori T, Mitsuyama K, Nagaoka M, et al. (2005) Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin Exp Immunol 140: 417-426.
36. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, et al. (2004) Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53: 1617-1623.
37. Singh B, Read S, Asseman C, Malmstrom V, Mottet C, et al. (2001) Control of intestinal inflammation by regulatory T cells. Immunol Rev 182: 190-200.
38. Mowat AM, Donachie AM, Parker LA, Robson NC, Beacock-Sharp H, et al. (2003) The role of dendritic cells in regulating mucosal immunity and tolerance. Novartis Found Symp 252: 291-302; discussion 302-295.
39. Liu Z, Zhang P, Ma Y, Chen H, Zhou Y, et al. (2011) Lactobacillus plantarum prevents the development of colitis in IL-10-deficient mouse by reducing the intestinal permeability. Mol Biol Rep 38: 1353-1361.
40. Mennigen R, Nolte K, Rijcken E, Utech M, Loeffler B, et al. (2009) Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol 296: G1140-1149.
41. Fasano A, (2011) Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev 91: 151-175.
42. Tlaskalova-Hogenova H, Stepankova R, Kozakova H, Hudcovic T, Vannucci L, et al. (2011) The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 8: 110-120.
43. Chen HQ, Yang J, Zhang M, Zhou YK, Shen TY, et al. (2010) Lactobacillus plantarum ameliorates colonic epithelial barrier dysfunction by modulating the apical junctional complex and PepT1 in IL-10 knockout mice. Am J Physiol Gastrointest Liver Physiol.
44. Sokol H, Seksik P, Rigottier-Gois L, Lay C, Lepage P, et al. (2006) Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis 12: 106-111.
45. Tannock GW, Munro K, Harmsen HJ, Welling GW, Smart J, et al. (2000) Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. Appl Environ Microbiol 66: 2578-2588.
46. Boyer M, Wisniewski-Dye F, (2009) Cell-cell signalling in bacteria: not simply a matter of quorum. FEMS Microbiol Ecol 70: 1-19.
47. Jamuna M, Jeevaratnam K, (2004) Isolation and characterization of lactobacilli from some traditional fermented foods and evaluation of the bacteriocins. J Gen Appl Microbiol 50: 79-90.
48. Mondel M, Schroeder BO, Zimmermann K, Huber H, Nuding S, et al. (2009) Probiotic E. coli treatment mediates antimicrobial human beta-defensin synthesis and fecal excretion in humans. Mucosal Immunol 2: 166-172.
49. MacDonald TT, Monteleone G, Pender SL, (2000) Recent developments in the immunology of inflammatory bowel disease. Scand J Immunol 51: 2-9.
50. Madara JL, Stafford J, (1989) Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers. J Clin Invest 83: 724-727.
51. Llopis M, Antolin M, Carol M, Borruel N, Casellas F, et al. (2009) Lactobacillus casei downregulates commensals' inflammatory signals in Crohn's disease mucosa. Inflamm Bowel Dis 15: 275-283.
52. Thomas CM, Versalovic J, (2010) Probiotics-host communication: Modulation of signaling pathways in the intestine. Gut Microbes 1: 148-163.
53. Chuang L, Wu KG, Pai C, Hsieh PS, Tsai JJ, et al. (2007) Heat-killed cells of lactobacilli skew the immune response toward T helper 1 polarization in mouse splenocytes and dendritic cell-treated T cells. J Agric Food Chem 55: 11080-11086.
54. Delcenserie V, Martel D, Lamoureux M, Amiot J, Boutin Y, et al. (2008) Immunomodulatory effects of probiotics in the intestinal tract. Curr Issues Mol Biol 10: 37-54.
55. Biswas A, Wilmanski J, Forsman H, Hrncir T, Hao L, et al. (2011) Negative regulation of Toll-like receptor signaling plays an essential role in homeostasis of the intestine. Eur J Immunol 41: 182-194.
56. Zhao Y, Karypis G, (2003) Clustering in life sciences. Methods Mol Biol 224: 183-218.